{
    "2019-09-03": [
        [
            {
                "time": "2019-09-01",
                "original_text": "华兰生物：梁平单采血浆站取得单采血浆许可证",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "单采血浆站",
                        "许可证"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-01",
                "original_text": "继续看好医药核心资产，坚守创新、消费和器械【西南医药|0901周报】",
                "features": {
                    "keywords": [
                        "医药核心资产",
                        "创新",
                        "消费",
                        "器械"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-01",
                "original_text": "【国元医药】2019H1汇总分析：业绩与行情分化持续，强者恒强 盈利能力下降",
                "features": {
                    "keywords": [
                        "国元医药",
                        "2019H1",
                        "业绩分化",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-09-01",
                "original_text": "【医药】江琦、祝嘉琦：医药板块2019H1分析暨9月月报：产业结构调整，子板块分化明显，把握结构性机会-20190901",
                "features": {
                    "keywords": [
                        "医药板块",
                        "2019H1",
                        "产业结构调整",
                        "子板块分化",
                        "结构性机会"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}